Bayer AG Stock Price Increases Following European Commission Approval
Bayer AG, a German healthcare company specializing in pharmaceuticals and agricultural products, has experienced a rise in its stock price. The company’s shares have increased by 52 cents, with the current price exceeding 26.80 euros.
The stock price surge is attributed to the European Commission’s approval of Bayer’s Eylea 8 mg for extended dosing in retinal diseases. This approval allows for treatment intervals of up to six months, which is expected to benefit patients with certain netzhauterkrankungen.
Key Details
- Current stock price: 26.80 euros
- Increase from previous day: 52 cents
- Approval granted by: European Commission
- Product approved: Eylea 8 mg for extended dosing in retinal diseases
Market Performance
Bayer AG’s stock has been performing well, with the current price placing it ahead of the Euro Stoxx 50.